172 related articles for article (PubMed ID: 9562234)
1. Relationship between pharmacokinetic half-life and pharmacodynamic half-life in effect-time modeling.
Keller F; Czock D; Zellner D; Giehl M
Int J Clin Pharmacol Ther; 1998 Mar; 36(3):168-75. PubMed ID: 9562234
[TBL] [Abstract][Full Text] [Related]
2. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling.
Meibohm B; Derendorf H
Int J Clin Pharmacol Ther; 1997 Oct; 35(10):401-13. PubMed ID: 9352388
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6% and propofol 1%.
Knibbe CA; Zuideveld KP; DeJongh J; Kuks PF; Aarts LP; Danhof M
Clin Pharmacol Ther; 2002 Dec; 72(6):670-84. PubMed ID: 12496748
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic-pharmacodynamic modeling of the anticonvulsant and electroencephalogram effects of phenytoin in rats.
Della Paschoa OE; Mandema JW; Voskuyl RA; Danhof M
J Pharmacol Exp Ther; 1998 Feb; 284(2):460-6. PubMed ID: 9454785
[TBL] [Abstract][Full Text] [Related]
5. Concentration-effect relationship of delta-9-tetrahydrocannabiol and prediction of psychotropic effects after smoking marijuana.
Harder S; Rietbrock S
Int J Clin Pharmacol Ther; 1997 Apr; 35(4):155-9. PubMed ID: 9112136
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic-pharmacodynamic relationship.
Baggot JD
Ann Rech Vet; 1990; 21 Suppl 1():29S-40S. PubMed ID: 2080844
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats: assessment of rapid functional adaptation.
Cox EH; Kuipers JA; Danhof M
Br J Pharmacol; 1998 Aug; 124(7):1534-40. PubMed ID: 9723968
[TBL] [Abstract][Full Text] [Related]
8. The relationships between half-life (t1/2) and mean residence time (MRT) in the two-compartment open body model.
Sobol E; Bialer M
Biopharm Drug Dispos; 2004 May; 25(4):157-62. PubMed ID: 15108218
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and pharmacodynamic modeling in vivo.
Holford NH; Sheiner LB
Crit Rev Bioeng; 1981; 5(4):273-322. PubMed ID: 7023829
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of intranasal versus intravenous fentanyl in patients with pain after oral surgery.
Foster D; Upton R; Christrup L; Popper L
Ann Pharmacother; 2008 Oct; 42(10):1380-7. PubMed ID: 18728103
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
[TBL] [Abstract][Full Text] [Related]
12. Predictors of onset and offset of drug effect.
Schnider TW; Minto CF
Eur J Anaesthesiol Suppl; 2001; 23():26-31. PubMed ID: 11766242
[TBL] [Abstract][Full Text] [Related]
13. The impact of arteriovenous concentration differences on pharmacodynamic parameter estimates.
Tuk B; Danhof M; Mandema JW
J Pharmacokinet Biopharm; 1997 Feb; 25(1):39-62. PubMed ID: 9353693
[TBL] [Abstract][Full Text] [Related]
14. Models for assessing the relationship between drug concentration and drug effect in performance horses.
Kamerling SG; Owens JG
Br Vet J; 1994; 150(6):507-25. PubMed ID: 7850442
[TBL] [Abstract][Full Text] [Related]
15. First human exposure to exogenous single-dose oral estetrol in early postmenopausal women.
Visser M; Holinka CF; Coelingh Bennink HJ
Climacteric; 2008; 11 Suppl 1():31-40. PubMed ID: 18464021
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic-pharmacodynamic modeling of the psychomotor stimulant effect of cocaine after intravenous administration: timing performance deficits.
Lau CE; Ma F; Foster DM; Falk JL
J Pharmacol Exp Ther; 1999 Feb; 288(2):535-43. PubMed ID: 9918556
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
Smith WB; Dowell JA; Pratt RD
Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
[TBL] [Abstract][Full Text] [Related]
18. Modeling of the time-dependency of in vitro drug cytotoxicity and resistance.
Levasseur LM; Slocum HK; Rustum YM; Greco WR
Cancer Res; 1998 Dec; 58(24):5749-61. PubMed ID: 9865733
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of mesna-mediated plasma cysteine depletion.
Smith PF; Booker BM; Creaven P; Perez R; Pendyala L
J Clin Pharmacol; 2003 Dec; 43(12):1324-8. PubMed ID: 14615468
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic-pharmacodynamic and metabolite modeling with TopFit.
Tanswell P; Heinzel G; Weisenberger H; Roth W
Int J Clin Pharmacol Ther; 1995 Oct; 33(10):550-4. PubMed ID: 8574505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
